Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol
NCT00422552 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2007-06-22
Summary
The purpose of this study is to assess the change in inspiratory capacity and lung function in patients with chronic obstructive pulmonary disease when treated with indacaterol compared to placebo and formoterol.
Conditions
Interventions
- DRUG
-
Indacaterol (QAB149)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Investigative site
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-09-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00463567 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
NCT01089127 ·Status: COMPLETED ·Phase: PHASE3
-
12-week Efficacy of Indacaterol
NCT01072448 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
NCT02418468 ·Status: COMPLETED ·Phase: PHASE4
-
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
NCT00636961 ·Status: COMPLETED ·Phase: PHASE2
-
Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT01543828 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT00620022 ·Status: COMPLETED ·Phase: PHASE3
-
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
NCT01778062 ·Status: COMPLETED ·Phase: PHASE3
-
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00396604 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00677807 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)
NCT00792805 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00669617 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00557466 ·Status: COMPLETED ·Phase: PHASE2
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00622635 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
NCT01715311 ·Status: WITHDRAWN ·Phase: PHASE4
-
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01604278 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
NCT00900731 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
NCT00821093 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
NCT01068600 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00615030 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients
NCT01727024 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
NCT00567996 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea
NCT01377051 ·Status: COMPLETED ·Phase: PHASE4
-
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00794157 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma
NCT00403637 ·Status: COMPLETED ·Phase: PHASE2/PHASE3